长春高新：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获批准

美港电讯11-05

【长春高新：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获批准】金十数据11月5日讯，长春高新公告，子公司金赛药业聚乙二醇重组人生长激素注射液新适应症上市申请获得国家药监局批准。适应症为用于特发性身材矮小，规格为27IU/4.5mg/0.5ml/瓶。金赛增是全球首个获批此适应症的长效生长激素，临床试验结果证实其显著改善患儿身高标准差积分，且安全性和耐受性良好。公司将积极推进该产品新适应症的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2481527986?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-05 17:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481527986","market":"hk","top_or_hot":-1,"title":"长春高新：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获批准","media":"美港电讯","content":"<div>\n<p>【长春高新：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获批准】金十数据11月5日讯，长春高新公告，子公司金赛药业聚乙二醇重组人生长激素注射液新适应症上市申请获得国家药监局批准。适应症为用于特发性身材矮小，规格为27IU/4.5mg/0.5ml/瓶。金赛增是全球首个获批此适应症的长效生长激素，临床试验结果证实其显著改善患儿身高标准差积分，且安全性和耐受性良好。公司将积极推进该产品新适应症的...</p>\n\n<a href=\"https://www.ushknews.com/\">网页链接</a>\n\n</div>\n","source":"live_meigang","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>长春高新：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n长春高新：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 17:51 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.ushknews.com/><strong>美港电讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【长春高新：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获批准】金十数据11月5日讯，长春高新公告，子公司金赛药业聚乙二醇重组人生长激素注射液新适应症上市申请获得国家药监局批准。适应症为用于特发性身材矮小，规格为27IU/4.5mg/0.5ml/瓶。金赛增是全球首个获批此适应症的长效生长激素，临床试验结果证实其显著改善患儿身高标准差积分，且安全性和耐受性良好。公司将积极推进该产品新适应症的...</p>\n\n<a href=\"https://www.ushknews.com/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0057","symbol_name":"长吉图板块","start_time":0,"source_url":"https://www.ushknews.com/","article_id":"2481527986","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481527986","pubTimestamp":1730800272,"sourceInfo":{"source_id":"live_meigang","name":"美港电讯"},"weMediaInfo":null,"summary":"【长春高新：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获批准】金十数据11月5日讯，长春高新公告，子公司金赛药业聚乙二醇重组人生长激素注射液新适应症上市申请获得国家药监局批准。适应症为用于特发","collect":0,"end_time":0,"defaultTopTitle":"ushknews.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK0057":"长吉图板块","03347":"泰格医药","BK0028":"国家队","BK0188":"融资融券","BK1583":"高瓴概念","BK1576":"医药外包概念","BK0046":"生物疫苗","BK0075":"新三板","BK0239":"医药制造","000661":"长春高新","BK1141":"生命科学工具和服务"},"translate_title":"Changchun High-tech: Subsidiary polyethylene glycol recombinant human growth hormone injection new indication marketing application approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000661":1,"03347":1},"content_text":"【长春高新：子公司聚乙二醇重组人生长激素注射液新适应症上市申请获批准】金十数据11月5日讯，长春高新公告，子公司金赛药业聚乙二醇重组人生长激素注射液新适应症上市申请获得国家药监局批准。适应症为用于特发性身材矮小，规格为27IU/4.5mg/0.5ml/瓶。金赛增是全球首个获批此适应症的长效生长激素，临床试验结果证实其显著改善患儿身高标准差积分，且安全性和耐受性良好。公司将积极推进该产品新适应症的市场推广工作。","kind":null,"is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481527986"}